Leif Niclas Fredrik Löwgren
Director/Board Member bij Omnivation AB
Profiel
Leif Niclas Fredrik Löwgren is currently a Director at Omnivation AB.
He was previously a Director at Copperstone Resources AB, QuiaPEG Pharmaceuticals AB, NextCell Pharma AB, and Quiapeg Pharmaceuticals Holding AB.
Mr. Löwgren holds an MBA from the University of Stockholm.
Actieve functies van Leif Niclas Fredrik Löwgren
Bedrijven | Functie | Begin |
---|---|---|
Omnivation AB | Director/Board Member | - |
Eerdere bekende functies van Leif Niclas Fredrik Löwgren
Bedrijven | Functie | Einde |
---|---|---|
COPPERSTONE RESOURCES AB | Director/Board Member | 14-05-2019 |
NEXTCELL PHARMA AB | Director/Board Member | - |
QUIAPEG PHARMACEUTICALS HOLDING AB | Director/Board Member | - |
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Director/Board Member | - |
Opleiding van Leif Niclas Fredrik Löwgren
University of Stockholm | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
COPPERSTONE RESOURCES AB | Non-Energy Minerals |
NEXTCELL PHARMA AB | Health Technology |
QUIAPEG PHARMACEUTICALS HOLDING AB | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
QuiaPEG Pharmaceuticals AB
QuiaPEG Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology QuiaPEG Pharmaceuticals AB operates as biotech company developing biopharmaceuticals based on a proprietary PEGylation technology platform. The firm’s technology is applicable on proteins, peptides, and small molecules. It develops novel long-acting biopharmaceuticals for the treatment of metabolic disorders. The company was founded by Hans Marcus Bosson in 2012 and is headquartered in Solna, Sweden. | Health Technology |
Omnivation AB |